P A Gurbel

Summary

Affiliation: Sinai Hospital of Baltimore
Country: USA

Publications

  1. ncbi The association of cigarette smoking with enhanced platelet inhibition by clopidogrel
    Kevin P Bliden
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 52:531-3. 2008
  2. ncbi Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting
    Mark J Antonino
    Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
    Am J Cardiol 103:1546-50. 2009
  3. ncbi Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease
    Paul A Gurbel
    Paul A Gurbel, MD Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Curr Treat Options Cardiovasc Med 11:22-32. 2009
  4. ncbi Drug insight: Clopidogrel nonresponsiveness
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Nat Clin Pract Cardiovasc Med 3:387-95. 2006
  5. ncbi Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Building, Baltimore, MD 21215, USA
    Thromb Res 119:563-70. 2007
  6. ncbi Clopidogrel resistance: implications for coronary stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Curr Pharm Des 12:1261-9. 2006
  7. ncbi Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Baltimore, MD 21215, USA
    Circulation 121:1188-99. 2010
  8. ncbi Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 46:1827-32. 2005
  9. ncbi Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 46:1820-6. 2005
  10. ncbi Genotyping: one piece of the puzzle to personalize antiplatelet therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Sinai Hospital of Baltimore, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 56:112-6. 2010

Collaborators

Detail Information

Publications101 found, 100 shown here

  1. ncbi The association of cigarette smoking with enhanced platelet inhibition by clopidogrel
    Kevin P Bliden
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 52:531-3. 2008
    ..The purpose of this study was to examine the effect of cigarette smoking on the platelet response to clopidogrel...
  2. ncbi Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting
    Mark J Antonino
    Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
    Am J Cardiol 103:1546-50. 2009
    ..04) and between specific inflammation markers (p < or = 0.02). In conclusion, in addition to markedly lowering platelet reactivity to adenosine diphosphate, long-term clopidogrel therapy is associated with an anti-inflammatory effect...
  3. ncbi Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease
    Paul A Gurbel
    Paul A Gurbel, MD Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Curr Treat Options Cardiovasc Med 11:22-32. 2009
    ..T.E.N.T. Thrombosis Study and future research will likely support the current concepts and lead to personalized treatment regimens that will optimize antiplatelet therapy...
  4. ncbi Drug insight: Clopidogrel nonresponsiveness
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Nat Clin Pract Cardiovasc Med 3:387-95. 2006
    ..The aim of this article is to provide a comprehensive and current review of clopidogrel response variability and nonresponsiveness...
  5. ncbi Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Building, Baltimore, MD 21215, USA
    Thromb Res 119:563-70. 2007
    ..However, the effect of the clopidogrel loading dose on the rate of thrombin-induced platelet-fibrin clot formation is unknown in this patient population...
  6. ncbi Clopidogrel resistance: implications for coronary stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Curr Pharm Des 12:1261-9. 2006
    ..The mechanisms of the response variability to clopidogrel remain incompletely defined. The contribution of intra- and extracellular pathways are under investigation...
  7. ncbi Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Baltimore, MD 21215, USA
    Circulation 121:1188-99. 2010
    ..The antiplatelet effects of the Platelet Inhibition and Patient Outcomes (PLATO) trial dose of ticagrelor in patients nonresponsive to clopidogrel and after they switch agents are unknown...
  8. ncbi Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 46:1827-32. 2005
    ..We investigated whether patients who suffered subacute stent thrombosis (SAT) have higher post-treatment reactivity than those who do not encounter stent thrombosis...
  9. ncbi Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 46:1820-6. 2005
    ..We investigated the relation of high ex vivo platelet reactivity, rapid fibrin generation, and high thrombin-induced clot strength to postdischarge ischemic events in patients undergoing percutaneous coronary intervention (PCI)...
  10. ncbi Genotyping: one piece of the puzzle to personalize antiplatelet therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Sinai Hospital of Baltimore, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 56:112-6. 2010
    ..Prospective clinical trials to test new algorithms for optimal personalized antiplatelet therapy are needed to provide the evidence base required for the routine adoption of genotyping into clinical practice...
  11. ncbi The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 45:1392-6. 2005
    ..We determined the effect of clopidogrel dosing on the incidence of nonresponsiveness (NR) and high post-treatment platelet aggregation (post-PA)...
  12. ncbi Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 160:346-54. 2010
    ..Ex vivo platelet function measurements may facilitate risk stratification and personalized antiplatelet therapy...
  13. ncbi Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Bldg, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 111:1153-9. 2005
    ..Moreover, limited information is available on the antiplatelet pharmacodynamics of a 300-mg versus a 600-mg clopidogrel loading dose, and the comparative effect of eptifibatide with these regimens is unknown...
  14. ncbi The platelet-related effects of tenecteplase versus alteplase versus reteplase
    Paul A Gurbel
    Sinai Center for Thrombosis Research, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Blood Coagul Fibrinolysis 16:1-7. 2005
    ..These findings may be directly relevant to the effect of alteplase on reperfusion and to future studies using combined platelet inhibitors and thrombolytic therapy...
  15. ncbi Platelet activation in myocardial ischemic syndromes
    Paul A Gurbel
    John Hopkins University School of Medicine, Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Avenue, Baltimore, MD 21215, USA
    Expert Rev Cardiovasc Ther 2:535-45. 2004
    ....
  16. ncbi Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Platelets 15:95-9. 2004
    ..These finding suggest insufficient platelet inhibition. The clinical importance of these findings should be further investigated to establish the potential link between insufficient platelet inhibition, stent thrombosis, and restenosis...
  17. ncbi Ticagrelor for the treatment of arterial thrombosis
    Paul A Gurbel
    Sinai Hospital of Baltimore, Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Expert Opin Pharmacother 11:2251-9. 2010
    ..Thus, it is both appropriate and timely to review available data and provide a comprehensive review of ticagrelor...
  18. ncbi The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Avenue, Baltimore, MD 21215, USA
    Thromb Res 112:9-12. 2003
    ..Marked variability in activation and reactivity were observed despite aspirin therapy...
  19. ncbi Aspirin and clopidogrel resistance: consideration and management
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Interv Cardiol 19:439-48. 2006
    ..A higher aspirin dose and strict compliance to therapy may overcome the occurrence of "aspirin resistance" in selected patients. A higher clopidogrel dose may be considered in patients exhibiting clopidogrel nonresponsiveness...
  20. ncbi Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 120:2577-85. 2009
    ..This is the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using the PLATO (PLATelet inhibition and patient Outcomes) trial loading dose (180 mg) with a high loading dose (600 mg) of clopidogrel...
  21. ncbi The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
    J Interv Cardiol 21:S10-7. 2008
    ..In the highest risk patients with elevated cardiac biomarkers indicative of myonecrosis, current guidelines support the use of early therapy with glycoprotein IIb/IIIa inhibition, aspirin, and clopidogrel...
  22. ncbi Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Department of Medicine, Sinai Hospital, Baltimore, Maryland 21215, USA
    Platelets 19:595-604. 2008
    ..The study is a step towards a personalized medicine approach to guide the intensity of antiplatelet therapy...
  23. ncbi Antiplatelet treatment of cardiovascular disease: a translational research perspective
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA
    Pol Arch Med Wewn 118:289-97. 2008
    ..Finally, based on the current evidence platelet reactivity may become a standard of care risk factor measured in all patients with cardiovascular disease...
  24. ncbi Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Blood Coagul Fibrinolysis 19:268-75. 2008
    ..Point-of-service measurements of platelet-fibrin clot characteristics may lead to more intensified antithrombotic therapy and reduced mortality in selected patients...
  25. ncbi Prasugrel, a third generation thienopyridine and potent platelet inhibitor
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Curr Opin Investig Drugs 9:324-36. 2008
    ..The companies were expected to launch the drug in the US by the end of 2008...
  26. ncbi Diagnostics for aspirin resistance
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Mol Diagn Ther 12:55-6. 2008
  27. ncbi The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA
    Platelets 20:97-104. 2009
    ..Larger studies are required to solidify these observations and their clinical relevance...
  28. ncbi Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland 21215, USA
    Am J Cardiol 100:18M-25M. 2007
    ..Large prospective studies designed to identify which patients are at risk for stent thrombosis on the basis of platelet function testing are under way and may eventually lead to personalized antithrombotic therapy...
  29. ncbi Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Bldg, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 115:3156-64. 2007
    ..Our primary aim was to determine the degree of platelet aspirin responsiveness in patients, as measured by commonly used methods, and to study the relation of aspirin dose to platelet inhibition...
  30. ncbi Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Thromb Res 121:107-15. 2007
    ..The P2Y12 reactivity ratio (PRR) determined by vasodilator-stimulated phosphoprotein phosphorylation levels has been used to indicate the extent of P2Y(12) blockade...
  31. ncbi Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to
    Paul A Gurbel
    Sinai Center for Thrombosis Research, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    J Am Coll Cardiol 53:648-57. 2009
    ..The secondary aim was to study the relation of platelet aggregation and TIP-FCS to the occurrence of periprocedural infarction...
  32. ncbi Recent developments in clopidogrel pharmacology and their relation to clinical outcomes
    Paul A Gurbel
    Sinai Hospital of Baltimore, Sinai Center for Thrombosis Research, 2401 W Belvedere Avenue, Baltimore, MD 21215, USA
    Expert Opin Drug Metab Toxicol 5:989-1004. 2009
    ....
  33. ncbi The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients
    P A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Baltimore, MD 21215, USA
    J Thromb Haemost 8:43-53. 2010
    ..16%, P = 0.0004). CONCLUSIONS: HPR is reversibly overcome by a single 60-mg oral dose of elinogrel, a drug now being investigated in a phase 2 trial. CYP2C19*2 was associated with HPR during conventional dual antiplatelet therapy...
  34. ncbi Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 48:2186-91. 2006
    ..This study was performed to compare the effects of antiplatelet regimens on early inflammation and cardiac marker release after elective stenting...
  35. ncbi Clopidogrel resistance?
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Thromb Res 120:311-21. 2007
    ..Small scale investigations have suggested that nonresponsiveness may be associated with a heightened risk for adverse clinical events. The above findings have stimulated a close examination of clopidogrel metabolism...
  36. ncbi A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Platelets 14:481-3. 2003
  37. ncbi The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 161:598-604. 2011
    ..Because both predict cardiovascular events with similar risk ratios, CYP2C19 genotyping and HPR may provide complementary information to stratify risk and personalized DAPT in stented patients than either alone...
  38. ncbi Platelet activation after stenting with heparin-coated versus noncoated stents
    Paul A Gurbel
    Sinai Hospital, Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 146:E10. 2003
    ..However, reduced platelet activation has never been demonstrated in humans. The purpose of the current study was to investigate the effect of heparin coating on platelet activation after coronary artery stenting...
  39. ncbi Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Thromb Haemost 106:265-71. 2011
    ..Large-scale trials are ongoing that will investigate the role of personalised antiplatelet therapy in the PCI patient...
  40. ncbi Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study
    Paul A Gurbel
    Sinai Hospital, Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Avenue, Baltimore, MD, 21215, USA
    J Invasive Cardiol 14:584-9. 2002
    ..This finding may be related to superior scaffolding, resulting in a smoother luminal contour after implantation of a closed-cell stent...
  41. ncbi Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks
    Paul A Gurbel
    Sinai Center for Thrombosis Research, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Thromb Haemost 106:248-52. 2011
    ..However, in the absence of a large-scale prospective clinical trial, routine platelet function monitoring and modification of timing of surgery based on platelet function monitoring are currently not recommended...
  42. ncbi Correction of a saphenous vein graft to coronary vein anastamosis by selective retrograde coil-induced occlusion to arterialize the native vein
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Catheter Cardiovasc Interv 57:541-4. 2002
  43. ncbi Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215 5271, USA
    Am Heart J 145:239-47. 2003
    ..We sought to establish an optimal clopidogrel dosing regimen for sustained platelet inhibition in stented patients...
  44. ncbi Vorapaxar: a novel protease-activated receptor-1 inhibitor
    Paul A Gurbel
    Sinai Center for Thrombosis Research, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Expert Opin Investig Drugs 20:1445-53. 2011
    ..Future large-scale trials with goals addressing these concerns are needed to define the specific role of PAR-1 receptor inhibitor...
  45. ncbi Durability of platelet inhibition by clopidogrel
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Am J Cardiol 91:1123-5. 2003
  46. ncbi Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Bldg, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 107:2908-13. 2003
    ..Clopidogrel is administered to prevent stent thrombosis; however, the uniformity of platelet inhibition after treatment and the influence of pretreatment reactivity on drug response have not been described...
  47. ncbi Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 155:56-61. 2008
    ....
  48. ncbi Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy)
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Thromb Thrombolysis 14:213-9. 2002
    ..The effect of eptifibatide on these receptors was investigated in a substudy of the EARLY Trial...
  49. ncbi Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Am J Cardiol 90:312-5. 2002
  50. ncbi Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators
    V L Serebruany
    Union Memorial Hospital, Baltimore, MD, USA
    Stroke 29:235-8. 1998
    ..However, prospective data on the changes of platelet status in patients before the occurrence of hemorrhagic stroke after thrombolytic therapy are unavailable...
  51. ncbi The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
    Rev Cardiovasc Med 7:S20-8. 2006
    ..This review explores the available information linking platelet reactivity during and after PCI to the occurrence of adverse events, including myocardial infarction, recurrent ischemia within 6 months, and stent thrombosis...
  52. ncbi Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries
    P A Gurbel
    Union Memorial Hospital and St Agnes Hospital, Baltimore, Maryland, USA
    J Am Coll Cardiol 31:1466-73. 1998
    ..We sought to compare platelet characteristics after reteplase and alteplase therapy in the setting of the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)-III trial...
  53. ncbi Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy
    V L Serebruany
    Center for Thrombosis Research, Sinai Hosital of Baltimore, MD 21215, USA
    Eur J Heart Fail 1:243-9. 1999
    ..However, no data are available on the plasma levels of Platelet/Endothelial Cell Adhesion Molecule-1 (PECAM-1), and platelet-derived osteonectin in this growing population...
  54. ncbi Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction
    P A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Scand Cardiovasc J 34:53-8. 2000
    ..634). The data suggest that the baseline characteristics predict future platelet activity, and may prospectively identify patients who will benefit most from antiplatelet strategies after coronary thrombolysis...
  55. ncbi Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor
    V L Serebruany
    Heart Associates Research and Education Foundation, Union Memorial Hospital, Baltimore, MD 21218, USA
    Prostaglandins Leukot Essent Fatty Acids 56:135-42. 1997
    ..Ability of Mg, diltiazem, and leumedins to favorably modulate plasma prostanoid levels have direct clinical implications for the use of these agents in patients with coronary artery disease...
  56. ncbi Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction
    V L Serebruany
    Sinai Center for Thrombosis Research, Schapiro Research Building, Baltimore, Maryland 21215, USA
    J Thromb Thrombolysis 9:229-34. 2000
    ..The ability of MAC to favorably modulate the pre-reperfusion platelet status in such patients is of clinical importance, and further investigation in large-scale clinical trials seem warranted...
  57. ncbi Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department
    P A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 139:320-8. 2000
    ..Elevated P-selectin level also has been observed in the clinical setting of myocardial ischemia and reperfusion; however, its utility in differentiating cardiac from noncardiac origins of chest pain is unknown...
  58. ncbi Prasugrel
    Udaya S Tantry
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Expert Opin Investig Drugs 15:1627-33. 2006
    ..The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness...
  59. ncbi Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 136:398-405. 1998
    ..Platelets play an important role in the natural history of acute myocardial infarction (AMI)...
  60. ncbi Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department
    V L Serebruany
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, MD 21215, USA
    J Thromb Thrombolysis 11:155-62. 2001
    ..We sought to determine whether the combined measurement of platelet and necrosis markers would improve risk stratification, and yield higher diagnostic utility in patients presenting to the emergency department with chest pain...
  61. ncbi Soluble PECAM-1, but not P-selectin, nor osteonectin identify acute myocardial infarction in patients presenting with chest pain
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital of Baltimore, MD 21215, USA
    Cardiology 91:50-5. 1999
    ..Increased plasma PECAM-1 may serve as a useful marker in the early detection of patients with AMI. Larger studies will be necessary to confirm the utility of soluble PECAM-1 in identifying AMI among patients presenting with chest pain...
  62. ncbi Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA
    Arterioscler Thromb Vasc Biol 19:153-8. 1999
    ..Further investigation of the possible role of PECAM-1 and the relationship between its soluble and platelet fractions in AMI are warranted...
  63. ncbi Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial)
    V L Serebruany
    Johns Hopkins University, Sinai Hospital, Baltimore, MD, USA
    Thromb Res 101:427-33. 2001
    ....
  64. ncbi Uniform platelet activation exists before coronary stent implantation despite aspirin therapy
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 142:611-6. 2001
    ..Enhanced platelet aggregation and receptor expression unquestionably occur after coronary stent implantation; however, the functional characteristics of platelets before stenting have not been fully elucidated...
  65. ncbi Platelet function and fibrinolytic agents: two sides of a coin?
    K P Callahan
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Cardiology 95:55-60. 2001
    ..This review summarizes the latest and often confusing data on the interaction between fibrinolytic therapy and platelets in certain in vitro, animal and clinical scenarios...
  66. ncbi Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy)
    Victor L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, MD, USA
    Am Heart J 146:91-8. 2003
    ..We measured platelet characteristics during chronic treatment in patients with coronary artery disease enrolled in the Roxifiban Oral Compound Kinetics Evaluation Trial (ROCKET-I)...
  67. ncbi Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors
    V L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, MD, USA
    Pharmacol Res 43:453-62. 2001
    ..The documented anti-platelet effects of sertraline and NDMS may be directly related to the mortality benefits of SSRIs after ischemic events including myocardial infarction and stroke...
  68. ncbi The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study
    Joseph DiChiara
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Diabetes 56:3014-9. 2007
    ..Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients...
  69. ncbi Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study
    Udaya S Tantry
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Platelets 21:360-7. 2010
    ..Further studies are required to investigate the primary mechanisms linking the above processes associated with a prothrombotic state resulting in clinical destabilization of the disease...
  70. ncbi Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation
    Udaya S Tantry
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 46:1705-9. 2005
    ..4%) was resistant to aspirin treatment. CONCLUSIONS: Platelet aspirin resistance assessed by methods that directly indicate inhibition of cyclooxygenase is rare in compliant patients with coronary artery disease...
  71. ncbi Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients
    Joseph DiChiara
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Platelets 18:414-23. 2007
    ..These data suggest that VerifyNow may identify a generalized high platelet reactivity phenotype...
  72. ncbi Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Kevin P Bliden
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 49:657-66. 2007
    ....
  73. ncbi Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry
    Victor L Serebruany
    Johns Hopkins University, Sinai Hospital, Baltimore, MD, USA
    Pathophysiol Haemost Thromb 32:8-15. 2002
    ..Taken together, opposite to our expectations, major clinical characteristics of heart failure did not correlate well with the platelet characteristics investigated in this study...
  74. ncbi Platelet function monitoring in patients with coronary artery disease
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
    J Am Coll Cardiol 50:1822-34. 2007
    ....
  75. ncbi Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists
    Rolf P Kreutz
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Blood Coagul Fibrinolysis 18:713-8. 2007
    ..These findings support a pro-aggregatory state that, in part, explains the thrombotic events shown by epidemiological studies...
  76. ncbi The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy
    Anand Singla
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 158:784.e1-6. 2009
    ..However, the relation of platelet reactivity to glycemic control is less studied in patients on dual antiplatelet therapy...
  77. ncbi The difference between clopidogrel responsiveness and posttreatment platelet reactivity
    Waiel M Samara
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Thromb Res 115:89-94. 2005
    ..Posttreatment platelet reactivity is a better measure of thrombotic risk than responsiveness to clopidogrel...
  78. ncbi Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy
    Victor L Serebruany
    Sinai Hospital, Johns Hopkins University, Baltimore, MD, USA
    Am Heart J 145:636-42. 2003
    ..Therefore, the success of fibrinolytic therapy may be dependent on its direct effects on platelets...
  79. ncbi The role of platelet receptors and adhesion molecules in coronary artery disease
    Waiel M Samara
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Coron Artery Dis 14:65-79. 2003
    ..Moreover, knowledge of the mechanisms of cellular crosstalk will lead to important advances in the development of better antithrombotic therapies...
  80. ncbi Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction
    Raymond D Bahr
    St. Agnes Hospital, Baltimore, Maryland, USA
    Am J Cardiol 90:310-2. 2002
  81. ncbi Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 143:1068-75. 2002
    ..We sought to determine whether platelet activity in patients with heart failure is related to an ischemic versus nonischemic etiologic condition, clinical disease severity, or adverse clinical outcomes...
  82. ncbi Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy
    V L Serebruany
    Emergency Departments and Critical Care Units, St Agnes and Union Memorial Hospitals, Baltimore, MD 21215, USA
    Cardiology 90:37-42. 1998
    ..Long-term aspirin therapy mildly reduces baseline platelet activity; however, this degree of relative platelet inhibition does not appear to be cardioprotective...
  83. ncbi Stent thrombosis: role of compliance and nonresponsiveness to antiplatelet therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
    Rev Cardiovasc Med 8:S19-26. 2007
    ..Early identification of vulnerable patients and definition of the role of antiplatelet nonresponsiveness in the development of stent thrombosis should be the focus of future diagnostic and therapeutic strategies...
  84. ncbi Platelet monitoring for PCI: is it really necessary?
    U S Tantry
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Hamostaseologie 29:368-75. 2009
    ....
  85. ncbi The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain: are we comparing apples with oranges
    V L Serebruany
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Thromb Res 96:51-6. 1999
    ..If P-selectin is to become a diagnostic tool for differentiating an etiology of chest pain, standardized measurements must be defined for each model of flow cytometer...
  86. ncbi Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy
    P A Gurbel
    Sinai Hospital, Baltimore, Maryland 21215, USA
    Am J Cardiol 87:774-7, A7. 2001
    ..A peak in soluble P-selectin levels at 3 hours after thrombolytic therapy and lower baseline platelet P-selectin were associated with successful thrombolysis...
  87. ncbi Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies
    Richard C Becker
    Duke University School of Medicine, Durham, North Carolina, United States
    Thromb Haemost 103:535-44. 2010
    ..of reversible and irreversible mechanisms of P2Y12 inhibition to bleeding risk, posing the question, "Is it not only how much but how a platelet P2Y12 receptor is inhibited that determines the attributable safety profile?"..
  88. ncbi AZD6140
    Udaya S Tantry
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Expert Opin Investig Drugs 16:225-9. 2007
    ..It has fast onset and offset actions that may be advantageous in patients who may have to undergo immediate surgery...
  89. ncbi Adhesion molecules, platelet activation, and cardiovascular risk
    Paul A Gurbel
    Am Heart J 143:196-8. 2002
  90. ncbi The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study
    David P Faxon
    Los Angeles County Medical Center and the University of Southern California School of Medicine, Los Angeles, California 60637, USA
    J Am Coll Cardiol 40:1199-204. 2002
    ..The purpose of this study was to determine whether Hu23F2G (LeukoArrest), an antibody to the CD11/CD18 integrin receptors, would reduce infarct size in patients undergoing primary angioplasty for an acute myocardial infarction...
  91. ncbi Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
    Wei C Lau
    Department of Anesthesiology, University of Michigan Health System, 1G323 University Hospital, Box 0048, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0048, USA
    Circulation 109:166-71. 2004
    ..Because the prodrug clopidogrel is activated by hepatic cytochrome P450 (CYP) 3A4, we hypothesized that interindividual variability in clopidogrel efficacy might be related to interindividual differences in CYP3A4 metabolic activity...
  92. ncbi Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure
    Karen E Joynt
    Department of Medicine Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 93:783-5. 2004
    ..Baseline angiotensin-converting enzyme inhibitor plus beta-blocker use were associated with lower levels of CRP; no relation was found between CRP levels and aspirin or statin use...
  93. ncbi Resistance to antiplatelet drugs: current status and future research
    Udaya S Tantry
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W. Belvedere Ave, Baltimore, MD 21215, USA
    Expert Opin Pharmacother 6:2027-45. 2005
    ....
  94. ncbi What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?
    Udaya S Tantry
    Catheter Cardiovasc Interv 66:597-8. 2005
  95. ncbi [The role of clopidogrel in cardiovascular diseases]
    Paul A Gurbel
    Pol Arch Med Wewn 117:207-9. 2007
  96. ncbi Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4
    Wei C Lau
    Medical Director Cardiovascular Center Operating Rooms, Cardiovascular Anesthesiology, University of Michigan Health System, Ann Arbor, Michigan, USA
    Pharm Res 23:2691-708. 2006
    ..Further investigation or guidelines are needed to optimize antiplatelet treatment strategies to identify and treat patients resistant to aspirin and/or clopidogrel...
  97. ncbi Clinical applications of antiplatelet therapy
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Rev Cardiovasc Med 7:130-46; quiz 148-9. 2006
    ..Nonresponsiveness to clopidogrel treatment has been suggested as a risk factor for the occurrence of ischemic events and stent thrombosis...
  98. ncbi Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level
    Barry E Bleske
    University of Michigan, College of Pharmacy, Ann Arbor, Michigan 48109 1065, USA
    J Am Coll Cardiol 47:338-41. 2006
    ....
  99. ncbi Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel
    Paul A Gurbel
    J Am Coll Cardiol 51:261-3. 2008
  100. ncbi Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial
    James B Hermiller
    St. Vincent's Hospital, Indianapolis, Indiana, USA
    J Am Coll Cardiol 45:1172-9. 2005
    ..CONCLUSIONS: The site-specific delivery of paclitaxel after coronary stent implantation is highly effective in reducing clinical and angiographic restenosis in patients with diabetes mellitus...
  101. ncbi Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 48:2440-7. 2006
    ..This trial examined the relative clinical efficacy, angiographic outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus sirolimus-eluting stents (SES)...